We are live on ! Find out more
PHAT icon

Phathom Pharmaceuticals
PHAT

117 hedge funds and large institutions have $504M invested in Phathom Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 50 increasing their positions, 22 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

439% more call options, than puts

Call options by funds: $415K | Put options by funds: $77K

127% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 22

100% more funds holding in top 10

Funds holding in top 10: 4 → 8 (+4)

47% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 17

17.7% more ownership

Funds ownership: 77.04% → 94.74% (+18%)

11% more capital invested

Capital invested by funds: $453M → $504M (+$51.7M)

6% more funds holding

Funds holding: 110 → 117 (+7)

Holders
117
Holders Change
+7
Holders Change %
+6.36%
% of All Funds
1.71%
Holding in Top 10
8
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+100%
% of All Funds
0.12%
New
25
Increased
50
Reduced
22
Closed
17
Calls
$415K
Puts
$77K
Net Calls
+$338K
Net Calls Change
-$951K

Top Buyers

Rank Fund Capital Flow
1
NMC
NEA Management Company
Maryland
+$5.89M
2
Ensign Peak Advisors
Ensign Peak Advisors
Utah
+$4.72M
3
WP
Woodline Partners
California
+$3.07M
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$2.7M
5
BlackRock
BlackRock
New York
+$2.08M

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$4.32M
2
KCM
Kennedy Capital Management
Missouri
-$4.22M
3
MB
MPM BioImpact
Massachusetts
-$2.39M
4
ACM
Altium Capital Management
New York
-$2.28M
5
Citadel Advisors
Citadel Advisors
Florida
-$2.28M
Name Holding Trade Value Shares
Change 		Change in
Stake
N
26
Nuveen
North Carolina
$2.78M +$145K +16,775 +6%
Northern Trust
27
Northern Trust
Illinois
$2.65M +$181K +21,043 +8%
Two Sigma Investments
28
Two Sigma Investments
New York
$2.44M +$1.57M +182,794 +217%
Charles Schwab
29
Charles Schwab
California
$2.4M +$137K +15,843 +6%
Morgan Stanley
30
Morgan Stanley
New York
$2.27M +$1.47M +170,858 +218%
SAM
31
Simplify Asset Management
Nevada
$2.17M – – –
Goldman Sachs
32
Goldman Sachs
New York
$1.92M +$618K +71,711 +52%
Walleye Capital
33
Walleye Capital
New York
$1.85M +$1.01M +116,782 +137%
EC
34
EcoR1 Capital
California
$1.81M -$4.32M -501,520 -72%
Millennium Management
35
Millennium Management
New York
$1.55M +$264K +30,696 +22%
SVCM
36
Saturn V Capital Management
Texas
$1.46M +$1.38M +160,075 New
Wellington Management Group
37
Wellington Management Group
Massachusetts
$1.41M +$470K +54,581 +55%
JP Morgan Chase
38
JP Morgan Chase
New York
$1.33M +$11K +1,281 +0.9%
D.E. Shaw & Co
39
D.E. Shaw & Co
New York
$1.18M -$10.1K -1,175 -0.9%
Bank of New York Mellon
40
Bank of New York Mellon
New York
$971K +$97K +11,254 +12%
MCM
41
Moore Capital Management
New York
$913K +$172K +20,000 +25%
Ameriprise
42
Ameriprise
Minnesota
$751K +$610K +70,842 +621%
Bank of America
43
Bank of America
North Carolina
$747K +$243K +28,235 +53%
MB
44
MPM BioImpact
Massachusetts
$639K -$2.39M -277,332 -80%
Renaissance Technologies
45
Renaissance Technologies
New York
$599K +$565K +65,600 New
Jane Street
46
Jane Street
New York
$596K -$47.6K -5,530 -8%
PMAM
47
Penn Mutual Asset Management
Pennsylvania
$573K – – –
SSA
48
Schonfeld Strategic Advisors
New York
$557K +$192K +22,256 +57%
Swiss National Bank
49
Swiss National Bank
Switzerland
$511K -$36.2K -4,200 -7%
Susquehanna International Group
50
Susquehanna International Group
Pennsylvania
$478K +$451K +52,313 New
1
2
3 4 5

PHAT Hedge Fund Activity: Q4 2023 in Review

117 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Phathom Pharmaceuticals (PHAT) for Q4 2023, worth a combined $504M — up 11% from $453M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new PHAT positions and 17 closed out — a net gain of 8 holders — while 50 added to existing stakes and 22 trimmed.

The largest buyer was NEA Management Company, adding an estimated $5.89M. The largest seller was EcoR1 Capital, cutting an estimated $4.32M.

  • 117 institutional investors held Phathom Pharmaceuticals (PHAT) as of Q4 2023, up from 110 in Q3 2023.
  • Funds reported $504M of Phathom Pharmaceuticals stock for Q4 2023, up 11% quarter-over-quarter.
  • 25 funds opened new Phathom Pharmaceuticals positions in Q4 2023 and 17 closed out, a net change of +8 holders.
  • The largest Phathom Pharmaceuticals buyer in Q4 2023 was NEA Management Company, an estimated $5.89M added.
  • The largest Phathom Pharmaceuticals seller in Q4 2023 was EcoR1 Capital, an estimated $4.32M sold.

Based on aggregated 13F filings for Q4 2023.